VRAYQ — Viewray Share Price
Last trade - 00:00- $0.00m
- -$3.53m
- $102.21m
- 18
- 83
- 21
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -164.6% | ||
| Return on Equity | -108.91% | ||
| Operating Margin | -103.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 80.96 | 87.78 | 57.02 | 70.12 | 102.21 | 92.7 | 150.4 | 24.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ViewRay, Inc. is engaged in designing, manufacturing, and marketing the MRIdian MRI-Guided Radiation Therapy System. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The Company has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.
Directors
- Daniel Moore NEC (60)
- Scott Drake PRE (53)
- Zachary Stassen CFO (42)
- James Dempsey CSO (50)
- Karen Prange DRC (57)
- Caley Castelein IND (50)
- B. Kristine Johnson IND (69)
- Brian Roberts IND (50)
- Phillip Spencer IND (58)
- Gail Wilensky IND (77)
- Kevin Xie IND (50)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- July 21st, 2015
- Public Since
- November 4th, 2014
- No. of Shareholders
- 71
- No. of Employees
- 295
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 183,402,038
- Address
- 2 Thermo Fisher Way, OAKWOOD VILLAGE, 44146-6536
- Web
- https://viewray.com/
- Phone
- +1 4407033210
- Auditors
- Deloitte & Touche LLP
Upcoming Events for VRAYQ
Similar to VRAYQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 24:02 UTC, shares in Viewray are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Viewray last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Viewray share price has underperformed the S&P500 Index by -100% over the past year.
The overall consensus recommendation for Viewray is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Viewray does not currently pay a dividend.
Viewray does not currently pay a dividend.
Viewray does not currently pay a dividend.
To buy shares in Viewray you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Viewray had a market capitalisation of $0.00m.
Here are the trading details for Viewray:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: VRAYQ
Based on an overall assessment of its quality, value and momentum Viewray is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Viewray is $1.00. That is 99999900% above the last closing price of $0.00.
Analysts covering Viewray currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Viewray. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in Viewray were trading -100% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Viewray PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Viewray's management team is headed by:
- Daniel Moore - NEC
- Scott Drake - PRE
- Zachary Stassen - CFO
- James Dempsey - CSO
- Karen Prange - DRC
- Caley Castelein - IND
- B. Kristine Johnson - IND
- Brian Roberts - IND
- Phillip Spencer - IND
- Gail Wilensky - IND
- Kevin Xie - IND